Nifedipine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Nifedipine

Examples of brand names: Adalat [DE]

ATC code: C08CA05

Main use (for orientation): Hypertension; angina

Documented research summary

Preclinical finding for the pair: nifedipine reduced CBD-induced Ca2+ elevation in rat hippocampal cells. Neuromuscular study with very high CBD/nifedipine concentrations provides mechanistic context only. No human pharmacokinetic evidence; withdrawal pilot and cannabis-arteritis treatment are not interaction evidence.

Uncertainties and limitations

A cellular Ca2+ signal is not a blood-pressure/pharmacokinetic endpoint in humans.

Neuromuscular-study abstract describes a nifedipine experiment, but no extractable pair-specific effect; a research lead, not proven enhancement.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0403

Type of result: Preclinical mechanistic finding

Observation: Nifedipine reduced CBD-induced intracellular Ca2+ elevation by approximately 50%.

Mechanism: L-type Ca2+-channel contribution to the CBD signal

Study type: Cultured rat hippocampal cells

Context studied: CBD 1 µM; nifedipine 20 µM; glia/neurons.

Clinical interpretation: Interpret within the stated study context; no independent dosage or treatment recommendation.

Limitations and uncertainties: Cellular signal, not a clinical blood-pressure or concentration study; not evidence of therapeutic synergy.

Original sources for this finding: Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells. [RMED16386766]

References and access status

[RLABEL_D0210] PROCARDIA XL (NIFEDIPINE) TABLET, FILM COATED, EXTENDED RELEASE [PFIZER LABORATORIES DIV PFIZER INC]

Original source / bibliographic reference

Authors: Regulatory product information; respective marketing authorisation holder

Year: 2026

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[RMED16386766] Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells.

Original source / bibliographic reference

Authors: Drysdale AJ, Ryan D, Pertwee RG, Platt B.

Year: 2006

Source type: Original publication; see finding for study type

DOI: 10.1016/j.neuropharm.2005.11.008

PMID: 16386766

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility